A week af­ter up­dat­ing their S-1 in search of at least $115 mil­lion on the hot biotech IPO mar­ket, Po­sei­da Ther­a­peu­tics says it’s al­so raised a fresh ven­ture round — a lit­tle more than a year af­ter its last.

The first time around, af­ter Po­sei­da de­layed its IPO dur­ing a gov­ern­ment shut­down, the biotech re­port­ed a $150 mil­lion C round. This time around, it’s adding $110 mil­lion more from Fi­deli­ty Man­age­ment Re­search Com­pa­ny and oth­ers.

There’s no word in the biotech’s state­ment on No­var­tis, which bought up half of the eq­ui­ty for the Se­ries C cash with a $75 mil­lion in­vest­ment.

Ac­cord­ing to the SEC fil­ing, No­var­tis — which field­ed the first, some­what trou­bled CAR-T — owns 14.9% of the com­pa­ny, with Ma­lin in for 23.2%, though those num­bers may have changed now.

The big ben­e­fi­cia­ry is CEO Er­ic Os­tertag, who con­trols 12.6 mil­lion shares — 25.4% — through var­i­ous fam­i­ly trusts.

Po­sei­da’s big idea in­volves the use of a non-vi­ral DNA tech that they say can be used to gath­er a big­ger con­cen­tra­tion of stem cell mem­o­ry T cells that can avoid the ex­haus­tion that lim­its the ef­fi­ca­cy of the pi­o­neers — a cen­tral theme in cell ther­a­py 2.0.

Os­tertag picked up his PhD in mol­e­c­u­lar bi­ol­o­gy at Penn and went on to a ca­reer that in­clud­ed a va­ri­ety of biotech star­tups.

While the US biosimilars industry has generally been a disappointment since its inception, with FDA approving 33 biosimilars since 2015, just a fraction of those have immediately followed their approvals with launches. And more than a handful of biosimilars for two of the biggest blockbusters of all time — AbbVie’s Humira and Amgen’s Enbrel — remain approved by FDA but still have not launched because of legal settlements.

As President Biden’s Build Back Better Act — and, with it, potentially the Democrats’ last shot at major drug pricing reforms in the foreseeable future — remains on life support, the Congressional Budget Office isn’t helping their case.

The CBO last week released a new slide deck, outlining an update to its model on how Medicare negotiations might take a bite out of new drugs making it to market. The new model estimates a 10% long-term reduction in the number of new drugs, whereas a previous CBO report from August estimated that 8% fewer new drugs will enter the market over 30 years.

There’s a giant need for cell and gene therapy manufacturing options going forward, as companies move to invest massively into that space. Ori Biotech is the latest, as the UK-based biotech announced it has secured more than $100 million in its oversubscribed Series B funding round Tuesday.

Novalis LifeSciences led the round. The Boston-based company is led by chairman Marijn Dekkers and partner Paul Meister, who built Thermo Fisher Scientific. Dekkers went on to become the CEO of Bayer, and is currently also the chairman at Ginkgo Bioworks.